Natural History Study of Patients With Hypophosphatasia (HPP)

Hypophosphatasia Clinical Trial

— NatHisHPP  

Official title:

Natural History Study of Adult and Pediatric Patients With Hypophosphatasia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02237625
• Other study ID #: Pro00049204
• Secondary ID: Pro00049204
• Status: Recruiting
• Start date: September 2014
• Est. completion date: September 2028

Study information

• Verified date: March 2024
• Source: Duke University
• Contact: Janet G Blount, BA
• Phone: 919-681-7962
• Email: janet.blount[@]duke.edu
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Hypophosphatasia (HPP) is a rare inherited metabolic disorder characterized by defective bone and teeth mineralization caused by mutations of the ALPL gene, which encodes for the tissue-nonspecific alkaline phosphatase (TNSALP) isozyme, resulting in decreased serum and bone alkaline phosphatase levels. To date, over 250 different mutations in the gene encoding TNSALP have been associated with HPP. Clinically, the loss of TNSALP function results in progressive skeletal impact as well as progressive impact on all other major organ systems. It clinically manifests as rickets in infants and children and osteomalacia at all ages. The severe form of the disease has been estimated to have a prevalence of about 1 in every 100,000 live births.

Description:

Inheritance can be autosomal recessive or dominant, and penetrance is variable resulting in a wide range of clinical expressivity, with a spectrum ranging from stillbirth without mineralized bone to early loss of teeth without bone symptoms. Depending on the age at diagnosis six clinical forms are currently recognized: perinatal (lethal), perinatal benign, infantile, childhood, adult and odontohypophosphatasia. Severe forms of HPP (perinatal and infantile) are inherited as an autosomal recessive trait and in milder forms (adult and odontohypophosphatasia) autosomal recessive and autosomal dominant inheritance coexist.

Because of the rarity of HPP as well as the side spectrum of both clinical presentation and inheritance patterns of the HPP trait, a natural history study cataloging specific clinical data with HPP would prove invaluable for future research into this disease. Specifically, it is our goal to create a comprehensive multi-discipline modality for care for hypophosphatasia patients, researching clinical manifestations of the disease such as extent of bone disease, ophthalmologic manifestations, orthopedic issues, renal issues, musculoskeletal manifestations as well as other more anecdotal findings such as those seen with cochlear implant failures and/or early menopause.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: September 2028
• Est. primary completion date: September 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients or their legal representative must provide written informed consent or, if applicable, qualify for waiver of consent.

• Patients must have a pre-established clinical diagnosis of HPP, as indicated by one or more of the following:

• Serum alkaline phosphatase (ALP) below the age-adjusted normal range

• Plasma PLP at least twice the upper limit of normal (no vitamin B6 administered for at least 1 week prior to determination)

• Evidence of osteopenia or osteomalacia on skeletal radiographs

• Genetic analysis fof the ALPL gene

• Must be current patient in the Duke University System.

Exclusion Criteria:

• Any patient without confirmation of clinical diagnosis of HPP.

Related Conditions & MeSH terms

• Hypophosphatasia

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Medical History of HPP Patients	Patient clinical data will be collected related to the diagnosis, onset, progression, treatment course and outcome for patients with HPP	100 years
Secondary	long-term efficacy of treatment modalities		100 years
Secondary	potential long term complications of the disease and/or treatment		100 years
Secondary	quality of life issues for patients living with hypophosphatasia		100 years